Pfizer Resolves Trovan Litigation In Nigeria, But More Suits Remain
Pfizer freed itself from the bulk of litigation over a 1996 Trovan clinical trial in Nigeria, agreeing to pay $75 million to settle civil and criminal charges brought by the Kano State government in Nigeria. The sum is a fraction of the more the $9 billion in claims the company was facing
You may also be interested in...
Last month, a federal appeals panel jolted Pfizer by ruling that dozens of Nigerians can sue the drugmaker in a U.S. court over its handling of a 1996 clinical trial for its Trovan (trovafloxacin mesylate) antibiotic
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials